Zobrazeno 1 - 10
of 33
pro vyhledávání: '"András Makkos"'
Autor:
Tamara Szabados, Arnold Molnár, Éva Kenyeres, Kamilla Gömöri, Judit Pipis, Bence Pósa, András Makkos, Bence Ágg, Zoltán Giricz, Péter Ferdinandy, Anikó Görbe, Péter Bencsik
Publikováno v:
Antioxidants, Vol 13, Iss 6, p 674 (2024)
Introduction: Ischemic conditionings (ICon) were intensively investigated and several protective signaling pathways were identified. Previously, we have shown the role of matrix metalloproteinases (MMP) in myocardial ischemia/reperfusion injury (MIRI
Externí odkaz:
https://doaj.org/article/a998a5afca6e4aed86cfe654244162be
Autor:
Tamás G. Gergely, Gábor B. Brenner, Regina N. Nagy, Nabil V. Sayour, András Makkos, Csenger Kovácsházi, Huimin Tian, Rainer Schulz, Zoltán Giricz, Anikó Görbe, Péter Ferdinandy
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 2, p 1585 (2023)
Lipid-lowering drugs have been shown to have cardioprotective effects but may have hidden cardiotoxic properties. Therefore, here we aimed to investigate if chronic treatment with the novel lipid-lowering drug bempedoic acid (BA) exerts hidden cardio
Externí odkaz:
https://doaj.org/article/17e87be51e874adc966ccfd71a3a1ed0
Autor:
Imre Vörös, Éva Sághy, Krisztina Pohóczky, András Makkos, Zsófia Onódi, Gábor B. Brenner, Tamás Baranyai, Bence Ágg, Barnabás Váradi, Ágnes Kemény, Przemyslaw Leszek, Anikó Görbe, Zoltán V. Varga, Zoltán Giricz, Rainer Schulz, Zsuzsanna Helyes, Péter Ferdinandy
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Little is known about the role of the neuropeptide somatostatin (SST) in myocardial ischemia/reperfusion injury and cardioprotection. Here, we investigated the direct cardiocytoprotective effect of SST on ischemia/reperfusion injury in cardiomyocyte
Externí odkaz:
https://doaj.org/article/dcbc88f896f543ad8ae2da1ca762c860
Autor:
Bennet Y. Weber, Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1055 (2022)
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during p
Externí odkaz:
https://doaj.org/article/be592a902bfc4549be3705bd481e22c9
Autor:
András Makkos, Ágnes Szántai, János Pálóczi, Judit Pipis, Bernadett Kiss, Paola Poggi, Péter Ferdinandy, Alexandros Chatgilialoglu, Anikó Görbe
Publikováno v:
Frontiers in Physiology, Vol 10 (2020)
IntroductionThe use of comorbidity models is crucial in cardioprotective drug development. Hypercholesterolemia causes endothelial and myocardial dysfunction, as well as aggravates ischemia/reperfusion (I/R)-induced myocardial injury. Endogenous card
Externí odkaz:
https://doaj.org/article/636eef7e34ba42c18c1c61b97bfa70a2
Autor:
Bence Ágg, Tamás Baranyai, András Makkos, Borbála Vető, Nóra Faragó, Ágnes Zvara, Zoltán Giricz, Dániel V. Veres, Péter Csermely, Tamás Arányi, László G. Puskás, Zoltán V. Varga, Péter Ferdinandy
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Little is known about the molecular mechanism including microRNAs (miRNA) in hypercholesterolemia-induced cardiac dysfunction. We aimed to explore novel hypercholesterolemia-induced pathway alterations in the heart by an unbiased approach ba
Externí odkaz:
https://doaj.org/article/13fda4bbf4064b339b6972ee7ccd3d94
Autor:
András Makkos, Bence Ágg, Zoltán V. Varga, Zoltán Giricz, Mariann Gyöngyösi, Dominika Lukovic, Rainer Schulz, Monika Barteková, Anikó Görbe, Péter Ferdinandy
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 17, p 9539 (2021)
Cardioprotective medications are still unmet clinical needs. We have previously identified several cardioprotective microRNAs (termed ProtectomiRs), the mRNA targets of which may reveal new drug targets for cardioprotection. Here we aimed to identify
Externí odkaz:
https://doaj.org/article/a42b766042de4b8daaf05d2034d34b99
Autor:
Tamás Baranyai, Zoltán Giricz, Zoltán V. Varga, Gábor Koncsos, Dominika Lukovic, András Makkos, Márta Sárközy, Noémi Pávó, András Jakab, Csilla Czimbalmos, Hajnalka Vágó, Zoltán Ruzsa, Levente Tóth, Rita Garamvölgyi, Béla Merkely, Rainer Schulz, Mariann Gyöngyösi, Péter Ferdinandy
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-13 (2017)
Abstract Background Cardioprotective value of ischemic post- (IPostC), remote (RIC) conditioning in acute myocardial infarction (AMI) is unclear in clinical trials. To evaluate cardioprotection, most translational animal studies and clinical trials u
Externí odkaz:
https://doaj.org/article/3dca34d2e189479c8358f789bf1943c2
Autor:
Zoltán Giricz, András Makkos, Rolf Schreckenberg, Jochen Pöling, Holger Lörchner, Krisztina Kiss, Péter Bencsik, Thomas Braun, Rainer Schulz, Péter Ferdinandy, Klaus-Dieter Schlüter
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 9, p 3359 (2020)
Swiprosin-1 (EFhD2) is a molecule that triggers structural adaptation of isolated adult rat cardiomyocytes to cell culture conditions by initiating a process known as cell spreading. This process mimics central aspects of cardiac remodeling, as it oc
Externí odkaz:
https://doaj.org/article/cca3a751dabb4f58a172afacda757c09
Autor:
Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi, Nabil V. Sayour, Tamás G. Gergely, Bernadett Kiss, Anikó Görbe, Éva Sághy, Zoltán S. Zádori, Bernadette Lázár, Tamás Baranyai, Richárd S. Varga, Zoltán Husti, András Varró, László Tóthfalusi, Rainer Schulz, István Baczkó, Zoltán Giricz, Péter Ferdinandy
Publikováno v:
Cells, Vol 9, Iss 3, p 551 (2020)
Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the
Externí odkaz:
https://doaj.org/article/e64b79f188254c80abf4399ea382fcad